PHXM
Income statement / Annual
Last year (2022), PHAXIAM Therapeutics S.A.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, PHAXIAM Therapeutics S.A.'s net income was -$227,000.00.
See PHAXIAM Therapeutics S.A.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$19.72 M
|
$10.78 M
|
$4.37 M
|
$1.80 M
|
| Cost of Revenue |
$2.91 M |
$5.38 M |
$57.58 M |
$52.19 M |
$33.47 M |
$25.46 M |
$19.72 M |
$10.78 M |
$4.37 M |
$2.83 M |
| Gross Profit |
-$2.91 M |
-$5.38 M |
-$57.58 M |
-$52.19 M |
-$33.47 M |
-$25.46 M |
$0.00 |
$0.00 |
$0.00 |
-$1.02 M |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-0.57 |
| Research and Development
Expenses |
$19.91 M
|
$45.10 M
|
$57.58 M
|
$52.19 M
|
$33.47 M
|
$25.46 M
|
$19.72 M
|
$10.78 M
|
$2.24 M
|
$2.50 M
|
| General & Administrative
Expenses |
$13.89 M
|
$15.10 M
|
$14.97 M
|
$17.16 M
|
$14.60 M
|
$8.79 M
|
$6.66 M
|
$7.62 M
|
$4.36 M
|
$3.55 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$13.89 M
|
$15.10 M
|
$14.97 M
|
$17.16 M
|
$14.60 M
|
$8.79 M
|
$6.66 M
|
$7.62 M
|
$4.36 M
|
$3.55 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$27.15 M |
$56.52 M |
$68.83 M |
$64.07 M |
$43.62 M |
$30.89 M |
$22.39 M |
$15.58 M |
$4.58 M |
$4.26 M |
| Cost And Expenses |
$27.15 M |
$56.52 M |
$68.83 M |
$64.07 M |
$43.62 M |
$30.89 M |
$22.39 M |
$15.58 M |
$8.95 M |
$7.09 M |
| Interest Income |
$4.45 M |
$13,000.00 |
$889,000.00 |
$2.95 M |
$163,000.00 |
$539,000.00 |
$545,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$1.36 M |
$2.14 M |
$5.35 M |
$1.53 M |
$9,000.00 |
$3.18 M |
$4,000.00 |
$5,000.00 |
$6,801.00 |
$4,656.00 |
| Depreciation &
Amortization |
$2.91 M
|
$5.38 M
|
$4.99 M
|
$4.22 M
|
$797,000.00
|
$532,000.00
|
$425,000.00
|
$288,000.00
|
$276,522.00
|
$180,297.00
|
| EBITDA |
-$22.69 M
|
-$47.46 M
|
-$67.94 M
|
-$61.13 M
|
-$37.42 M
|
-$30.35 M
|
-$21.47 M
|
-$15.25 M
|
-$8.74 M
|
-$8.02 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
-1.09 |
-1.41 |
-2 |
-4.45 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
-1.14
|
-1.45
|
-2.05
|
-3.93
|
| Total Other
Income/Expenses Net |
$32.38 M
|
-$949,000.00
|
-$747,000.00
|
-$67.94 M
|
$5.40 M
|
-$2.64 M
|
$4.31 M
|
-$1.65 M
|
-$1.46 M
|
-$1.10 M
|
| Income Before Tax |
$293,000.00 |
-$53.80 M |
-$73.30 M |
-$62.66 M |
-$38.22 M |
-$33.53 M |
-$21.90 M |
-$15.02 M |
-$8.88 M |
-$8.18 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
-1.11
|
-1.39
|
-2.03
|
-4.54
|
| Income Tax Expense |
$521,000.00 |
$2,000.00 |
$3,000.00 |
-$1,000.00 |
$2,000.00 |
-$3,000.00 |
$10,000.00 |
-$3,000.00 |
-$20,158.00 |
-$40,018.00 |
| Net Income |
-$227,000.00 |
-$53.80 M |
-$73.30 M |
-$62.66 M |
-$38.22 M |
-$33.53 M |
-$21.91 M |
-$15.01 M |
-$8.86 M |
-$8.14 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
-1.11 |
-1.39 |
-2.03 |
-4.52 |
| EPS |
-0.0073 |
-2.27 |
-3.99 |
-3.49 |
-2.13 |
-1.87 |
-2.74 |
-2.16 |
-1.51 |
-17.4 |
| EPS Diluted |
-0.0073 |
-2.27 |
-3.99 |
-3.49 |
-2.13 |
-1.87 |
-2.74 |
-2.16 |
-1.51 |
-17.4 |
| Weighted Average Shares
Out |
$31.02 M
|
$23.69 M
|
$18.39 M
|
$17.94 M
|
$17.94 M
|
$17.94 M
|
$7.98 M
|
$6.96 M
|
$5.87 M
|
$468,615.00
|
| Weighted Average Shares
Out Diluted |
$31.02 M
|
$23.69 M
|
$18.39 M
|
$17.94 M
|
$17.94 M
|
$17.94 M
|
$7.98 M
|
$6.96 M
|
$5.87 M
|
$468,615.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
